Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: Studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 636-642

  Bergen, Phillip J ^a   Li, Jian ^a   Nation, Roger L ^a   Turnidge, John D ^b   Coulthard, Kingsley ^b,c   Milne, Robert W ^c  

^a MONASH UNIVERSITY   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Colistin methanesulphonate; Dosage regimens; Multidrug resistance; Pharmacodynamics; Pharmacokinetics

Indexed keywords

COLISTIMETHATE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG POTENCY; GROWTH REGULATION; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA;

EID: 40049095690     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm511     Document Type: Article

References (37)

1. Jones RN. Resistance patterns among nosocomial pathogens: Trends over the past few years. Chest 2001; 119: 397S-404S.
2. Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42: 657-68.
3. Livermore DM. The threat from the pink corner. Ann Med 2003; 35 226-34.
4. Berlana D, Llop JM, Fort E et al. Use of colistin in the treatment of multiple-drug-resistant Gram-negative infections. Am J Health Syst Pharm 2005; 62: 39-47.
5. Boutiba-Ben Boubaker I, Boukadida J, Triki O et al. Outbreak of nosocomial urinary tract infections due to a multidrug resistant Pseudomonas aeruginosa. Pathol Biol 2003; 51: 147-50.
6. Michalopoulos A, Kasiakou SK, Rosmarakis ES et al. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis 2005; 37: 142-5.
7. Karabinis A, Paramythiotou E, Mylona-Petropoulo D et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis 2004; 38: E7-9.
8. Li J, Nation RL, Milne RW et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25.
9. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
10. Li J, Nation RL, Turnidge JD et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
11. Linden PK, Kusne S, Coley K et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: E154-60.
12. Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684-704.
13. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24: 284-95.
14. Giamarellou H, Antoniadou A. Antipseudomonal antibiotics. Med Clin North Am 2001; 85: 19-42.
15. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli: Report from the SENTRY antimicrobial surveillance programme 2001-2004. Clin Microbiol Infect 2006; 12: 315-21.
16. Gilad J, Eskira S, Riesenberg K et al. Emergence of nosocomial colistin-resistant Acinetobacter baumannii. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 2005. Abstract K-1292, p. 333. American Society for Microbiology, Washington, DC, USA.
17. Beveridge EG, Martin AJ. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1967; 29: 125-35.
18. Schwartz BS, Warren MR, Barkley FA et al. Microbiological and pharmacological studies of colistin sulfate and sodium colistin methanesulfonate. Antibiot Annu 1959; 7: 41-60.
19. Li J, Milne RW, Nation RL et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53: 837-40.
20. Li J, Coulthard K, Milne R et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003, 52: 987-92.
21. Li J, Rayner CR, Nation RL et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49: 4814-5.
22. Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-8.
23. Conway SP, Pond MN, Watson A et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52: 987-93.
24. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-11.
25. Michalopoulos AS, Tsiodras S, Rellos K et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant bacteria: The renaissance of an old antibiotic. Gram-negative Clin. Microbiol Infect 2005; 11: 115-21.
26. Gunderson BW, Ibrahim KH, Hovde LB et al. Synergistic-activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 905-9.
27. Rosenvinge A, Pressler T, Hoiby N. Colistin intravenously is a safe and effective treatment of multidrug-resistant microorganisms in cystic fibrosis. J Cyst Fibros 2005; 4: S32.
28. Coly-Mycin M Parenteral [package insert]. 2006. Mosman, NSW, Australia. Link Medical Products Pty Ltd.
29. Coly-Mycin M Parenteral [package insert]. 2005. Bristol, TN. Monarch Pharmaceuticals.
30. Li J, Turnidge J, Milne R et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 781-5.r
31. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
32. Li J, Milne RW, Nation RL et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47: 1364-70.
33. Li J, Milne RW, Nation RL et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 761: 167-75.
34. Li J, Milne RW, Nation RL et al. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47: 1766-70.
35. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83.
36. Reed MD, Stern RC, O'Riordan MA et al. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41: 645-54.
37. Tam VH, Schilling AN, Vo G et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3624-30.